AstraZeneca’s Durvalumab/Tremelimumab Combo Holds Its Own In NSCLC
This article was originally published in The Pink Sheet Daily
Phase Ib results for PD-L1/CTLA-4 combination look competitive, but editorial questions whether the company has moved too fast with development in response to intense market pressure.
You may also be interested in...
In Bristol’s CheckMate 067, PD-1 monotherapy performs as well as the PD-1/CTLA-4 combination in melanoma patients with higher expression of the PD-L1 biomarker, a finding that implies a personalized immunotherapy approach in the future.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.